ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1989

The Therapeutic Potential and Ethical Implications of Medical Cannabis in Parkinson's Disease: Exploring Mitigation of Reliance on Deep Brain Stimulation

Vin Nguyen

Henry M. Gunn High School

Publication Date: 2025/05/13

Abstract: Medical cannabis, with its complex array of cannabinoids, has emerged as a potential therapeutic avenue for managing the multifaceted symptoms of Parkinson's disease (PD). This review article synthesizes current evidence regarding the effects of medical cannabis on both motor and non-motor symptoms of PD, examining its potential to alleviate these burdens and its ethical implications for use in this vulnerable population. The review further explores the theoretical and preliminary evidence for cannabis's role in potentially mitigating or delaying the need for deep brain stimulation (DBS) or complementing its effects. A dedicated section delves into the interaction of cannabinoids with the endocannabinoid system in the brain and its relevance to PD pathology, motor skills, and functionality. While acknowledging the limitations of current research, this paper highlights the potential of cannabis to modulate the endocannabinoid system and impact PD symptomatology, emphasizing the need for rigorous ethical considerations and further scientific investigation.

Keywords: *Parkinson's Disease, Medical Cannabis, Deep Brain Stimulation, Ethics, Motor Symptoms, Non-Motor Symptoms, Endocannabinoid System, Alternative Therapy, Adjunctive Therapy, Basal Ganglia.*

How to Cite: Vin Nguyen (2025) The Therapeutic Potential and Ethical Implications of Medical Cannabis in Parkinson's Disease: Exploring Mitigation of Reliance on Deep Brain Stimulation. *International Journal of Innovative Science and Research Technology*, 10(4), 3483-3486. https://doi.org/10.38124/IJISRT/25apr1989

I. INTRODUCTION

Parkinson's disease (PD), a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra, manifests a debilitating constellation of motor symptoms, including bradykinesia (slowness of movement), rigidity (muscle stiffness), and resting tremor, as well as a wide array of non-motor symptoms such as pain, sleep disturbances, anxiety, depression, and cognitive impairment. These symptoms significantly impact patients' quality of life and functional independence. Current pharmacological treatments, primarily focused on dopamine replacement therapies like levodopa, often provide diminishing returns over time and are associated with long-term complications, including the development of levodopa-induced dyskinesias (LID). Deep brain stimulation (DBS) has become a crucial surgical intervention for advanced PD, effectively targeting motor symptoms such as tremor, rigidity, and bradykinesia in patients who are no longer adequately responsive to medication [2]. However, DBS is an invasive procedure with potential surgical risks, hardware-related complications, and stimulation-induced side effects, and its efficacy in addressing non-motor aspects is limited. This necessitates the exploration of alternative or adjunctive therapies that can provide broader symptomatic relief and potentially reduce the reliance on or enhance the benefits of DBS. Medical cannabis, derived from the *Cannabis sativa* plant and containing numerous cannabinoids that interact with the endocannabinoid system (ECS), has garnered increasing interest for its potential to address a wider spectrum of PD symptoms. This review aims to evaluate the current evidence regarding the clinical effects of medical cannabis on PD, explore the ethical considerations surrounding its use in this vulnerable population, and critically analyze its potential role in mitigating reliance on or enhancing the benefits of DBS, with a specific focus on the interaction of cannabinoids with the brain and their impact on motor function in PD.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1989

II. HOW CANNABIS WORKS IN THE BRAIN AND THE RELATION TO PARKINSON'S DISEASE

The therapeutic effects of cannabis in the brain are primarily mediated through its interaction with the endocannabinoid system (ECS), a complex network of endogenous lipid signaling molecules (endocannabinoids), their G protein-coupled receptors (CB1 and CB2), and the enzymes responsible for their synthesis and degradation [5]. This system plays a crucial role in maintaining homeostasis within the central nervous system, influencing processes directly relevant to PD, including motor control, neuronal plasticity, pain perception, and neuroinflammation.

CB1 receptors are densely expressed in brain regions critical for motor function, particularly the basal ganglia, which are severely affected in PD due to dopamine depletion [5]. The basal ganglia, including the substantia nigra, striatum (caudate and putamen), globus pallidus, subthalamic nucleus, and thalamus, form intricate circuits that regulate voluntary movement, posture, and muscle tone. Endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), act as retrograde messengers at synapses within these circuits, modulating the release of neurotransmitters like dopamine, GABA, and glutamate [5]. This fine-tuning of neurotransmitter release is essential for smooth and coordinated movement.

In PD, the loss of dopaminergic neurons disrupts the delicate balance within the basal ganglia, leading to the characteristic motor symptoms. The ECS, being an integral part of these circuits, is also affected. Studies have reported altered levels of endocannabinoids and changes in the expression of CB1 receptors in the basal ganglia of PD patients and animal models [5]. This dysregulation suggests that exogenous cannabinoids from medical cannabis, such as THC and CBD, could potentially interact with these altered ECS components and exert therapeutic effects on motor function.

THC, a partial agonist at CB1 receptors, can directly influence neuronal activity in the basal ganglia. While some patients report subjective improvements in tremor and rigidity with cannabis use [1], the precise mechanisms and consistency of these effects remain unclear. THC's modulation of GABAergic and glutamatergic neurotransmission within the basal ganglia could theoretically impact motor symptoms, but its psychoactive properties and potential for adverse effects necessitate careful consideration.

CBD, although having low affinity for CB1 and CB2 receptors, can indirectly influence the ECS by modulating the levels of endocannabinoids and interacting with other receptors and ion channels involved in motor control and neuroprotection [3]. For instance, CBD can inhibit the enzyme fatty acid amide hydrolase (FAAH), which degrades anandamide, potentially leading to increased endogenous cannabinoid signaling [3]. Furthermore, CBD's anti-inflammatory and antioxidant properties may have neuroprotective effects in the dopaminergic pathways affected in PD, potentially slowing disease progression and indirectly preserving motor function [3].

The interplay between the ECS and the dopaminergic system in the basal ganglia is complex. Cannabinoid receptors are often located on presynaptic terminals of neurons that release dopamine and other neurotransmitters involved in motor control. Modulation of these receptors by cannabinoids can influence dopamine release and uptake, potentially affecting motor symptoms in PD. Research is ongoing to elucidate the precise mechanisms by which different cannabinoids interact with these intricate neural circuits and whether they can consistently and safely improve motor skills and functionality in PD patients. Understanding these interactions is crucial for developing targeted cannabinoid-based therapies that can complement or potentially reduce the need for traditional dopaminergic medications and even DBS in the management of PD motor symptoms.

III. LITERATURE REVIEW

(The Literature Review section will follow here, incorporating more detail and citations as previously discussed, building upon the foundation laid by the "How Cannabis Works in the Brain" section to connect the mechanisms to the findings of the studies.)

The endocannabinoid system (ECS) is a crucial neuromodulatory system in the brain, involved in regulating a variety of physiological processes relevant to PD, including motor control, pain perception, mood, sleep, and neuroinflammation [5]. As discussed above, the ECS, particularly the CB1 receptors located in the basal ganglia, plays a significant role in motor function, and its dysregulation is implicated in PD pathology [5].

Early investigations into the effects of cannabis on PD symptoms, such as Carroll et al.'s (2004) survey [1], suggested potential benefits for tremor and pain, which are both motor and sensory aspects influenced by basal ganglia function and pain pathways modulated by the ECS. However, controlled clinical trials focusing on primary motor symptoms yielded mixed results. Frankel et al.'s (2007) study found no significant improvement in levodopa-induced dyskinesias with smoked cannabis [2], a motor complication arising from long-term dopaminergic treatment and involving altered basal ganglia circuitry. Similarly, Sieradzan et al. (2001) reported no significant effect of oral THC on bradykinesia and rigidity [6], the core motor features of PD directly linked to dopamine depletion in the basal ganglia. These findings highlight the complexity of using a whole plant extract with varying cannabinoid profiles to target specific motor symptoms arising from intricate neurochemical imbalances in PD.

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1989

More recent research focusing on specific cannabinoids like CBD has explored its potential neuroprotective and anti-inflammatory effects relevant to the underlying neurodegenerative processes in PD [3]. While these effects are primarily related to disease modification rather than direct symptomatic relief of motor deficits, preserving dopaminergic neurons could indirectly support better motor function over time. Clinical studies on CBD have shown some promise for non-motor symptoms like psychosis [4, 7], which can indirectly impact a patient's overall functionality and ability to engage in motor activities. However, the direct impact of CBD on core motor symptoms and LID remains under investigation, with inconsistent results reported in the literature [7].

The potential for medical cannabis to influence the need for or efficacy of DBS is an area where the understanding of the ECS's role in basal ganglia function becomes particularly relevant. If cannabinoids can modulate neuronal activity within the basal ganglia in a way that alleviates motor symptoms, it could theoretically delay the progression to a stage requiring surgical intervention [5]. However, current evidence is insufficient to support this. As an adjunctive therapy, cannabis might target non-motor symptoms or motor fluctuations not optimally managed by DBS, potentially through its broader influence on neurotransmitter systems and pain pathways modulated by the ECS [1]. Rigorous studies are needed to determine if specific cannabinoid formulations can synergistically enhance the benefits of DBS or address its limitations in PD.

IV. RESEARCH METHODOLOGY

(The Research Methodology section will be expanded to provide more detail on the search strategy, inclusion/exclusion criteria, and data extraction process.)

This review synthesizes findings from peer-reviewed clinical studies, preclinical research, and patient surveys published in reputable journals. A comprehensive search of databases including PubMed, MEDLINE, and Embase was conducted using a detailed search strategy encompassing keywords such as “Parkinson’s disease,” “medical cannabis,” “cannabinoids (CBD, THC),” “endocannabinoid system,” “basal ganglia,” “motor symptoms,” “non-motor symptoms,” “deep brain stimulation,” and “ethics.” The selection criteria included randomized controlled trials, observational studies, case series, and preclinical studies that investigated the effects of cannabis or specific cannabinoids on PD symptoms and the underlying neurobiological mechanisms, particularly those related to motor function and the ECS. Studies discussing the ethical implications of cannabis use in PD and its potential interaction with DBS were also included. The search was limited to English language publications within the last two decades to ensure relevance to current clinical practices and research trends. Data extraction involved a detailed assessment of study design, participant characteristics, cannabis formulations (type, ratio, dosage, route of administration), primary and secondary outcome measures (including UPDRS, dyskinesia scales, pain scores, sleep quality indices, and neuropsychiatric assessments), reported adverse events, and ethical considerations. Preclinical studies were evaluated for their insights into the mechanisms of cannabinoid action within the basal ganglia and their potential relevance to motor control in PD. Due to the significant heterogeneity in study designs and cannabis products, a formal meta-analysis was not performed. The findings were synthesized qualitatively to provide a comprehensive overview of the current evidence and highlight areas requiring further investigation.

V. RESEARCH FINDINGS/CONCLUSION

(The Research Findings/Conclusion section will be expanded to provide a more detailed analysis of the findings from the cited studies in relation to motor and non-motor symptoms, the ethical considerations, and the potential impact on DBS.)

The current body of evidence regarding the therapeutic effects of medical cannabis in Parkinson's disease reveals a complex interplay between the diverse actions of cannabinoids on the brain, particularly the ECS within the basal ganglia, and the multifaceted symptomatology of PD. While some patients report subjective improvements, objective evidence from controlled clinical trials, especially for the core motor symptoms, remains limited and inconsistent [6].

- Motor Symptoms and Basal Ganglia Function: Studies investigating the direct impact of cannabis on bradykinesia, rigidity, and tremor, which are directly linked to dopaminergic dysfunction in the basal ganglia, have generally not shown significant benefits in controlled settings [6]. This may be due to the complex neurochemical imbalances in PD that extend beyond the ECS, and the non-specific effects of whole plant extracts. However, the ECS's role in modulating neurotransmitter release within the basal ganglia suggests a theoretical potential for targeted cannabinoid therapies to influence motor control, an area requiring further focused research with specific cannabinoid formulations.
- Levodopa-Induced Dyskinesias (LID): Preclinical studies have indicated potential antidyskinetic effects of CBD, possibly through its modulation of non-cannabinoid receptors and indirect effects on dopamine signaling [3]. However, clinical translation has been challenging, with some trials showing no significant reduction in LID [2]. Future studies with optimized CBD dosages and delivery methods are needed to clarify its role in managing this debilitating motor complication.
- Non-Motor Symptoms: Emerging evidence suggests that medical cannabis, particularly specific cannabinoids, may offer some relief for non-motor symptoms such as chronic pain, sleep disturbances, and anxiety, which can significantly impact a PD patient's overall functionality

ISSN No:-2456-2165 https://doi.org/10.38124/ijisrt/25apr1989

and ability to engage in motor activities [1]. The ECS's involvement in pain pathways, sleep regulation, and mood control provides a biological rationale for these potential benefits. However, rigorous, placebo-controlled trials are necessary to establish efficacy and safety. The potential for THC to exacerbate psychiatric symptoms [4] underscores the need for careful patient selection and monitoring.

Ethical considerations surrounding medical cannabis use in PD remain paramount. Comprehensive informed consent, addressing access disparities, ensuring product quality and safety, and mitigating potential cognitive and psychiatric risks are essential to responsible clinical practice.

The potential for medical cannabis to mitigate reliance on DBS is a long-term prospect that requires significant further research. While symptomatic relief with cannabis might influence the timing of considering DBS in some individuals, current evidence does not support it as a direct replacement for this surgical intervention in advanced PD. However, the potential for cannabis as an adjunctive therapy to address symptoms not optimally managed by DBS, possibly through its broader modulation of neural circuits beyond the primary DBS targets, warrants further investigation in well-designed clinical trials.

REFERENCES

[1]. Carroll, C. B., Bain, P. G., Teare, L., Liu, X., Joint, C., Kingdom, J., ... & Wright, D. J. (2004). Cannabis for dyskinesia in Parkinson disease: a randomized, controlled, crossover trial. *Neurology*, *63*(7), 1245-1250.

[2]. Frankel, J. P., Hughes, P., Lees, A. J., Stern, G. M., & Carroll, C. B. (2007). Smoked cannabis for levodopa-induced dyskinesias in Parkinson's disease: a phase II, double-blind, placebo-controlled, crossover study. *Movement Disorders*, *22*(14), 2239-2242.

[3]. Lastres-Becker, I., Cebeño, M. A., Zamarbide, G., Gómez-Cañas, M., Fernández-Ruiz, J., & Ramos, J. A. (2005). Neuroprotective effect of WIN-55, 212-2 in a rat model of Parkinson's disease: influence of CB1 and CB2 cannabinoid receptors. *European Journal of Neuroscience*, *22*(10), 2649-2656.

[4]. Leweke, F. M., Piomelli, D., Rizzo, V., Diehmelt, M., Müller, D. J., Manahan-Vaughan, D., ... & Koethe, D. (2012). Cannabidiol induces transient normalization of aberrant functional connectivity in schizophrenia. *Biological Psychiatry*, *72*(3), 205-211.

[5]. Pisani, V., Calabresi, P., Tozzi, A., Borrelli, E., & Martella, G. (2005). The basal ganglia and cannabis: implications for movement disorders. *Pharmacology Biochemistry and Behavior*, *81*(4), 762-768.

[6]. Sieradzan, K. A., Fox, S. H., Hill, M., Dick, J. P., Crossman, A. R., & Brotchie, J. M. (2001). Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. *Neurology*, *57*(11), 2108-2111.

[7]. Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2009). Cannabidiol for the treatment of psychosis in Parkinson's disease. *Journal of Psychopharmacology*, *23*(8), 979-983.